trans-4-Methoxycinnamic acidCAS# 943-89-5 |
- 4-Methoxycinnamic acid
Catalog No.:BCN5037
CAS No.:830-09-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 943-89-5 | SDF | Download SDF |
| PubChem ID | 699414.0 | Appearance | Powder |
| Formula | C10H10O3 | M.Wt | 178.18 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (E)-3-(4-methoxyphenyl)prop-2-enoic acid | ||
| SMILES | COC1=CC=C(C=C1)C=CC(=O)O | ||
| Standard InChIKey | AFDXODALSZRGIH-QPJJXVBHSA-N | ||
| Standard InChI | InChI=1S/C10H10O3/c1-13-9-5-2-8(3-6-9)4-7-10(11)12/h2-7H,1H3,(H,11,12)/b7-4+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
trans-4-Methoxycinnamic acid Dilution Calculator
trans-4-Methoxycinnamic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.6123 mL | 28.0615 mL | 56.123 mL | 112.246 mL | 140.3076 mL |
| 5 mM | 1.1225 mL | 5.6123 mL | 11.2246 mL | 22.4492 mL | 28.0615 mL |
| 10 mM | 0.5612 mL | 2.8062 mL | 5.6123 mL | 11.2246 mL | 14.0308 mL |
| 50 mM | 0.1122 mL | 0.5612 mL | 1.1225 mL | 2.2449 mL | 2.8062 mL |
| 100 mM | 0.0561 mL | 0.2806 mL | 0.5612 mL | 1.1225 mL | 1.4031 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Saikogenin F
Catalog No.:BCX0619
CAS No.:14356-59-3
- 11-Oxo-Alpha-Amyrin
Catalog No.:BCX0618
CAS No.:2118-90-3
- 2-Methoxycinnamaldehyde
Catalog No.:BCX0617
CAS No.:60125-24-8
- 3’,5-dihydroxy-2-(4-hydroxybenzyl)3-methoxybibenzyl
Catalog No.:BCX0616
CAS No.:151538-57-7
- 3,4,5-Trimethoxytoluene
Catalog No.:BCX0615
CAS No.:6443-69-2
- Resveratrol-4'-O-β-D-(6''-O-galloy)-glucopyranoside
Catalog No.:BCX0614
CAS No.:64898-03-9
- 3,5-Dimethoxytoluene
Catalog No.:BCX0613
CAS No.:4179-19-5
- Oleanic aldehyde
Catalog No.:BCX0612
CAS No.:17020-22-3
- OJV-VI
Catalog No.:BCX0611
CAS No.:125150-67-6
- Stugeron
Catalog No.:BCX0610
CAS No.:298-57-7
- Arundamine
Catalog No.:BCX0609
CAS No.:475977-53-8
- 5’-inosinic acid
Catalog No.:BCX0608
CAS No.:131-99-7
- 6-Deoxy-D-glucose
Catalog No.:BCX0621
CAS No.:7658-08-4
- 2,3-Dimethoxybenzoic acid
Catalog No.:BCX0622
CAS No.:1521-38-6
- 1-Deoxyforskolin
Catalog No.:BCX0623
CAS No.:72963-77-0
- 4-Methoxy-1,2-benzenediol
Catalog No.:BCX0624
CAS No.:3934-97-2
- Yibeinoside A
Catalog No.:BCX0625
CAS No.:98985-24-1
- γ-sanshool
Catalog No.:BCX0626
CAS No.:78886-65-4
- (+)-Balanophonin
Catalog No.:BCX0627
CAS No.:215319-47-4
- Blestriarene A
Catalog No.:BCX0628
CAS No.:126721-53-7
- Creatinine
Catalog No.:BCX0629
CAS No.:60-27-5
- 1,1,1,1-Kestohexose
Catalog No.:BCX0630
CAS No.:62512-19-0
- Uric acid
Catalog No.:BCX0631
CAS No.:69-93-2
- Monoethyl fumaric acid
Catalog No.:BCX0632
CAS No.:2459-05-4
Xanthine oxidase inhibition study of isolated secondary metabolites from Dolichandrone spathacea (Bignoniaceae): In vitro and in silico approach.[Pubmed:38439949]
Saudi Pharm J. 2024 Apr;32(4):101980.
Xanthine oxidase (XO) has been widely recognized as a pivotal enzyme in developing hyperuricemia, primarily contributing to the excessive production of uric acid during purine metabolism in the liver. One of the standard treatment approaches involves reducing uric acid levels by inhibiting XO activity. In this study, the leaf extract of Dolichandrone spathacea, traditionally used in folk medicine, was found to inhibit XO activity in the ethyl acetate and butanol fractions at a concentration of 100 microg/mL, their values were 78.57 +/- 3.85 % (IC(50) = 55.93 +/- 5.73 microg/ml) and 69.43 +/- 8.68 % (IC(50) = 70.17 +/- 7.98 microg/ml), respectively. The potential XO inhibitory components were isolated by bioactivity assays and the HR-ESI-MS and NMR spectra system. The main constituents of leaf extracts of Dolichandrone spathacea, six compounds, namely trans-4-Methoxycinnamic acid (3), trans-3,4-dimethoxycinnamic acid (4), p-coumaric acid (5), martynoside (6), 6-O-(p-methoxy-E-cinnamoyl)-ajugol (7), and scolymoside (17), were identified as potent XO inhibitors with IC(50) values ranging from 19.34 +/- 1.63 muM to 64.50 +/- 0.94 muM. The enzyme kinetics indicated that compounds 3-5, 7, and 17 displayed competitive inhibition like allopurinol, while compound 6 displayed a mixed-type inhibition. Computational studies corroborated these experimental results, highlighting the interactions between potential metabolites and XO enzyme. The hydrogen bonds played crucial roles in the binding interaction, especially, scolymoside (17) forms a hydrogen bond with Mos3004, exhibited the lowest binding energy (-18.3286 kcal/mol) corresponding to the lowest IC(50) (19.34 +/- 1.63 muM). Furthermore, nine compounds were isolated for the first time from this plant. In conclusion, Dolichandrone spathacea and its constituents possess the potential to modulate the xanthine oxidase enzyme involved in metabolism.
